Updated On: 18 November, 2020 07:56 PM IST | Mumbai | IANS
Pfizer and BioNTech plan to apply "within days" to US regulators for emergency use approval

Photo used for representational purpose
Pfizer and its German partner BioNTech released a second batch of interim results on Wednesday, saying their two-dose coronavirus vaccine candidate is 95 per cent effective and also protects the most vulnerable people in older age groups from the risk of falling prey to the virus.
The company said that no serious side effects have shown up. The most common complaint was fatigue after the second vaccine dose, affecting about 4 per cent of the participants who got the shot.